Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report

BACKGROUND: Anaplastic lymphoma kinase tyrosine kinase inhibitors are standard therapeutic agents prescribed for anaplastic lymphoma kinase-positive non-small cell lung cancer, and treatment with these agents has been shown to contribute to long-term survival in patients. However, there is no consen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashizaki, Fumihiro, Tanaka, Arihito, Sekido, Yasutomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400211/
https://www.ncbi.nlm.nih.gov/pubmed/35999557
http://dx.doi.org/10.1186/s13256-022-03556-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400211/
https://www.ncbi.nlm.nih.gov/pubmed/35999557
http://dx.doi.org/10.1186/s13256-022-03556-8

Ejemplares similares